mtDNA was proposed to amplify necroptotic signaling via ZBP1 (Chen et al., 2018) and has since been suggested as a ZBP1 agonist in different cancer settings (Baik et al., 2021; Lei et al., 2023a; Yang et al., 2021) and myocardial infarction (Enzan et al., 2023). Here, ZBP1 is linked to myocardial infarction.